|
|
Improving the Therapeutic Ratio in Hodgkin Lymphoma Through the Use of Proton Therapy
Bradford S. Hoppe, MD, MPH1,
Stella Flampouri, PhD1,
James Lynch, MD2,
William Slayton, MD3,
Robert Zaiden, MD4,
Zuofeng Li, DSc1,
Nancy P. Mendenhall, MD1
, May 15, 2012
This review addresses the rationale and evidence for—and the challenges, cost implications, and future development of—proton therapy as an important part of the treatment strategy in Hodgkin lymphoma.
• Protons: Moving Therapy for Hodgkin Lymphoma in a Positive Direction
• Proton Radiotherapy: The Good, the Bad, and the Uncertain
Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
Catherine Thieblemont, MD, PhD1,
Frederic Davi, PhD2,
Maria-Elena Noguera, MD1,
Josette Brière, MD, PhD1,
Francesco Bertoni, MD3,
Emanuele Zucca, MD3,
Alexandra Traverse-Glehen, MD, PhD4,
Pascale Felman, MD4,
Françoise Berger, MD, PhD4,
Gilles Salles, MD, PhD4,
Bertrand Coiffier, MD, PhD4
, February 9, 2012
In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic marginal zone lymphoma.
• Splenic Lymphomas: Is There Still a Role for Splenectomy?
• Splenic Marginal Zone Lymphoma: Villous, Not Necessarily Villainous
Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma
Alexandra Traverse-Glehen, MD, PhD1, Francesco Bertoni, MD2, Catherine Thieblemont, MD, PhD3, Emanuele Zucca, MD2, Bertrand Coiffier, MD, PhD1, Françoise Berger, MD, PhD1, Gilles Salles, MD, PhD1
, January 17, 2012
The aim of this review is twofold: to summarize descriptions of the clinical presentation provided in published series in order to help clinicians recognize and treat patients, and to discuss diagnostic difficulties faced by hematopathologists when dealing with these lesions and others in the differential diagnosis that must be distinguished from one another.
• Nodal Marginal Zone Lymphoma: Impersonalized Medicine
• Nodal Marginal Zone Lymphoma: What Do We Really Know?
Patient With AML Develops Fungal Pneumonia and Osteomyelitis Following Treatment
October 24, 2011
A 58-year-old man developed acute myeloid leukemia. After responding to remission-induction high-dose chemotherapy, he received an allogeneic stem cell transplant that was complicated by a graft-versus-host reaction. While being treated for the latter with prednisone, tacrolimus (Prograf), and mycophenolate mofetil (CellCept), he developed both fungal pneumonia and osteomyelitis caused by Fusarium species.
|
Hematology Letters is a new blog for CancerNetwork written by Mojtaba Akhtari, MD of the University of Nebraska Medical Center, Omaha, Nebraska.
Designing the Perfect Business Card for Your Medical Practice C. Noel Henley, MD, May 11, 2012 Does your business card say anything substantive about the valuable work you do in your practice? Here’s how to re-design your next business card for maximum impact and engagement. The Five Biggest Medical Practice Marketing Mistakes James Doulgeris, May 10, 2012 There are best practices to marketing your practice, but often, success is more about knowing what not to do. Here are the five most common pitfalls …and how to avoid them. Can You Practice Medicine and Manage Your Practice? Rosemarie Nelson, May 9, 2012 Whether you practice alone, or in a group, if you're trying to see patients in this pay-for-volume environment and also run the business of your practice, you may be missing out on important opportunities.
LEUKEMIA & LYMPHOMA MEDICATIONS
SEARCHMEDICA SEARCH RESULTS
Find peer-reviewed literature and websites for practicing medical professionals
|
|